Aims Resting plasma levels of atrial natriuretic peptide and B-type natriuretic peptide rise with left ventricular dysfunction, but little is known about effects of cardiac ischaemia on atrial natriuretic peptide and B-type natriuretic peptide levels during exercise. We investigated exercise levels of atrial natriuretic peptide and B-type natriuretic peptide in patients with suspected angina to determine whether these measurements could improve non-invasive assessment of coronary disease severity.
Introduction
Atrial natriuretic peptide and B-type natriuretic peptide are secreted predominantly from storage granules in the atrial and ventricular myocardium, respectively, in response to changes in wall tension' 11 . During cardiac ischaemia, the initial diastolic dysfunction of the affected myocardium, and the later systolic dysfunction' 21 , cause an increase in atrial and ventricular wall tension. This acts as a stimulus for atrial natriuretic peptide and B-type natriuretic peptide secretion and increased release of both peptides has been demonstrated during acute myocardial ischaemia' 341 . As the plasma half-lives of atrial natriuretic peptides and B-type natriuretic peptides are short (approximately 2-6 min and 22 min respectively'
51
) and extra-cardiac release in man is negligible' 6 ' 71 , the increases in plasma levels during exercise should reflect acute changes in intracardiac pressures. It is well known that plasma levels of atrial natriuretic peptide and B-type natriuretic peptide are increased at rest in patients with impaired ventricular function' 81 . However, one surprising observation is that the increment in atrial natriuretic peptide levels following a saline load is reduced rather than increased in patients with left ventricular dysfunction' 9 '. Moreover, Yasuda et al. described impaired secretion of atrial natriuretic peptide after acute right ventricular infarction, which subsequently improved after right coronary angioplasty' 101 . These latter two observations raise the new concept that, in some circumstances, ischaemia can cause reduced endocrine function of the heart, i.e. reduced secretion of natriuretic peptides. To explore this concept further, we have now examined in detail the effects of chronic coronary artery disease on natriuretic peptide release, with the aim of dissecting out which aspects of cardiac disease may lead to impaired cardiac endocrine activity.
A second reason for our study was to assess whether exercise-induced increments in atrial natriuretic peptide/B-type natriuretic peptide levels could predict the severity of coronary artery disease. It was anticipated that the exercise-induced increments in atrial natriuretic peptide/B-type natriuretic peptide would be much greater in patients with two or three-vessel coronary disease than in patients without significant coronary occlusions and that this information may help to decide which patients should be further investigated with coronary angiography.
Methods
The study took place in a single teaching hospital. The study protocol was approved in advance by the local committee on medical research ethics. All participating patients gave full written consent.
Patients
The study population came from patients who had recently been investigated by coronary angiography for suspected angina pectoris. Exclusion criteria were: exercise-limiting non-cardiac disease; rest pain; previous coronary artery surgery; angiographic evidence of left main stem coronary stenosis; and echocardiographic or catheter evidence of severe aortic stenosis.
Coronary angiography
Single-plane coronary angiography was performed by one of three experienced operators who reported on the films with no knowledge of the results of the study exercise tests or natriuretic peptide levels. Resting left ventricular end-diastolic pressure was measured during held expiration. Stenosis of greater than 50% of a coronary artery or one of its major branches was considered significant.
Exercise testing
Within 2 weeks of coronary angiography the patients performed a standard symptom-limited exercise tolerance test according to the Bruce protocol. Betaadrenoreceptor antagonists were discontinued for 48 h prior to the test; all other medication was continued. Routine electrocardiographic monitoring (Marquette automated system) and blood pressure measurements (manual sphygmomanometer) were performed. Tests were terminated due to symptoms of chest pain, leg pain, breathlessness or fatigue or if pre-set electrocardiographic criteria (>4 mm ST segment depression at 2 mm after the J-point in any of the standard ECG leads) or haemodynamic criteria (maximal predicted heart rate achieved; or >10mmHg fall in systolic blood pressure) were reached. The physician supervising the tests was unaware of the results of coronary angiography.
Blood sampling
Prior to each exercise test the patients lay supine for 30 min and a resting venous blood sample was taken.
Further blood samples were taken from a cannula in a forearm vein at peak exercise. Samples were taken into chilled tubes containing edetic acid and aprotinin. Plasma was separated and stored at -70°C until the measurement of atrial natriuretic peptide-like immunoreactivity (ANP-li) and B-type natriuretic peptide-like immunoreactivity (BNP-li).
Natriuretic peptide assays
Each peptide was measured in all of the samples in a single assay run. Plasma was applied to C8 solid phase extraction columns which had been pretreated with 4 ml methanol, 4 ml distilled water and 4 ml 1% trifluoroacetic acid. The columns were washed with 9 ml of 1% trifluoroacetic and samples were eluted with 4 ml of 95% methanol and 1% trifluoroacetic. After drying, radioimmunoassay was performed with commercial kits supplied by Peninsula: a-ANP 1-28 (human, canine) (RIK-8798); BNP 32 (human (RIK-9086). Recovery was assessed using pooled plasma which had been spiked with samples of each peptide at a concentration of 128 pg . ml" '. The spiked sample and a blank sample were then processed according to the extraction procedure detailed above. Recovery was 88% for atrial natriuretic peptide and 86% for B-type natriuretic peptide. The coefficients of variability for each assay were: atrial natriuretic peptide inter-assay c.v. = ll-8%, intraassay c.v. = 12-6%; B-type natriuretic peptide inter-assay c.v.= 14-8%, intra-assay c.v.=9-9%.
Statistical analysis
Stepwise regression analysis was used to determine the independent effect of a range of factors on the resting and exercise levels of atrial natriuretic peptide and B-type natriuretic peptide. These factors were age, sex, exercise duration, ST segment shift during exercise, resting left ventricular end-diastolic pressure and the presence of stenotic disease of each coronary artery. Differences between the resting and exercise levels of natriuretic peptides in different groups were compared using analysis of variance (ANOVA). Statistical significance was accepted for P values <0-05.
Results
A total of 100 patients were recruited for the study; they are described in Table 1 . The exercise duration, diuretic and vasodilator drug therapy of the patients, divided according to coronary angiographic findings, are shown in Table 2 . The exercise duration was significantly lower in patients with stenotic disease involving both the left and right coronary arteries than in the other groups. Results of the multiple regression analysis to assess the effects of exercise parameters, coronary anatomy and Eur Heart J, Vol. 18, November 1997 left ventricular end-diastolic pressure on resting levels and exercise-induced increments of atrial natriuretic peptide and B-type natriuretic peptide are demonstrated in Table 3 . The effects of the extent and the distribution of coronary disease on resting LVEDP and levels of natriuretic peptides are demonstrated in Table 4 and in Fig. 1 . In summary, increasing age and female sex were significantly associated with higher resting atrial natriuretic peptide levels; age alone was associated with higher exercise atrial natriuretic peptide levels. Left ventricular end-diastolic pressure and disease of left anterior descending and circumflex coronary arteries were associated with increased resting B-type natriuretic peptide levels. The usual rise in B-type natriuretic peptide levels during exercise was independently reduced by disease of the right coronary artery.
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Discussion
These results demonstrate that coronary artery disease influences cardiac endocrine function independently of resting left ventricular function. One previous similar study has assessed the effect of exercise on atrial natriuretic peptide and B-type natriuretic peptide levels in only 16 patients with suspected ischaemic heart disease, with no coronary angiographic date'"
1 . In that limited study there was an increase in atrial natriuretic peptide levels on exercise in both the patients and in normal controls; B-type natriuretic peptide levels rose in the patients but not in the control group.
It is important to emphasize that in our study the group of patients with 'normal coronary arteries' are not normal controls but patients with chest pain who do not have evidence of significant epicardial coronary disease on angiography. These patients are likely to have a higher incidence of small vessel coronary disease and vasomotor dysfunction than the normal population. However, as we wished to test the possible clinical value of natriuretic peptide measurement in the assessment of patients with chest pain we chose a group of patients who were being investigated on clinical grounds. Moreover, to perform coronary angiography on asymptomatic control subjects for research purposes would have been unethical because of the risks involved.
The effects of coronary disease on the levels of B-type natriuretic peptide were distinct from the effects on atrial natriuretic peptide release, confirming separate control mechanisms for secretion of the two peptides, a phenomenon which has been described previously' 12 '. As expected, increased left ventricular end-diastolic pressure and stenotic disease of the left coronary circulation were associated with higher resting levels of B-type natriuretic peptide. Surprisingly, the presence of right coronary artery disease, either alone or in combination with disease of the left coronary arteries, resulted in suppression of the B-type natriuretic peptide response to exercise. A possible explanation for this observation is that when an area of myocardium becomes ischaemic, its endocrine activity is impaired and secretion of B-type natriuretic peptide is diminished. Therefore, if the left ventricle is predominantly affected, as in patients with left coronary disease but no significant right coronary disease, there will be an increase in left ventricular end-diastolic pressure during exercise which in turn will result in increased left atrial pressure, pulmonary hypertension and increased right ventricular wall tension. The right ventricle, which is not ischaemic, would then be stimulated to release B-type natriuretic peptide, which may have the effect of partly correcting the haemodynamic abnormalities. However, if there is also significant disease of the right coronary artery then the secretory function of the right ventricle will be inadequate and there will be no rise in B-type natriuretic peptide levels during the ischaemic episode. This concept is supported by the Yasuda et al. who found that following acute right ventricular infarction the cardiac endocrine reserve was diminished and was subsequently improved by early angioplasty to the right coronary artery' 10 '. An independent negative effect of ischaemia on exercise-induced B-type natriuretic peptide release may also explain why, in this study, the levels of natriuretic peptides were of no clinical value in assessing the severity of coronary artery disease.
The observed association between high resting atrial natriuretic peptide levels and increasing age has been well documented previously' 13 ' and it is interesting that this association persisted for exercise-induced increments of atrial natriuretic peptide release. There are several possible explanations for this, but an important factor is an age-related decline in renal function, resulting in reduced excretion of atrial natriuretic peptide' 141 . Coronary artery disease had no significant independent effect on resting or exercise levels of atrial natriuretic peptide. This was surprising as it was expected that cardiac ischaemia during exercise would cause an exaggerated rise in right and left atrial pressures, stimulating atrial natriuretic peptide release. Two possible confounding factors are the significantly lower exercise duration in patients with stenotic disease involving left and right coronary arteries (see Table 2 ) and the usage of vasodilator drugs such as nitrates and calcium antagonists which were not stopped before the treadmill test and which were taken by more patients in the coronary artery disease group than in the normal coronary artery group. It is known that drug treatment influences atrial natriuretic peptide release in patients with heart failure' 15 ' and these drugs may have blunted the secretory response both by limiting the degree of cardiac ischaemia during exercise and by modifying the haemodynamic consequences of ischaemia.
Drug treatment is also the most likely explanation for two other surprising findings which are demonstrated in Table 3 : firstly that the correlation between left ventricular end-diastolic pressure and resting levels of natriuretic peptides was weak; and secondly that the left ventricular end-diastolic pressure was lower in patients with coronary disease than in patients with normal coronary arteries. The effect of the vasodilator and diuretic medication, which was considerably more prevalent in those patients with coronary disease, would be to reduce both left ventricular end-diastolic pressure and natriuretic peptide release. A previous study has demonstrated that the relationship between natriuretic peptide levels and pulmonary capillary wedge pressure is distorted by vasodilator medication' 161 . Unfortunately, in routine clinical practice, if natriuretic peptide levels were to be used as a diagnostic tool in the assessment of chest pain, then it would be extremely difficult to control for the patient's treatment.
The lack of B-type natriuretic peptide response to exercise in right coronary artery disease could have important consequences. B-type natriuretic peptide is a potentially anti-ischaemic substance due to its effects as a mixed vasodilator 151 and its beneficial effects on ventricular diastolic relaxation' 17 '. These effects make the release of B-type natriuretic peptide an entirely appropriate anti-ischaemic response to cardiac ischaemia.
Loss of this response may significantly affect the exercise tolerance of patients with right coronary artery disease. Further work in this area is clearly required, especially as there are now therapeutic agents which can increase the activity of endogenous atrial natriuretic peptide and B-type natriuretic peptide' l8il9) and which may prove useful in patients with an impaired cardiac endocrine response to exercise, brought on by right coronary artery disease.
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